Medicenna Therapeutics Corp Stock Price, News & Analysis

Medicenna Therapeutics (OTCQX: MDNAF), a clinical-stage immunotherapy company specializing in Superkines development, held its annual shareholders meeting on September 25, 2025. The meeting saw a 55.75% turnout of issued and outstanding common shares, with all nominated directors successfully elected with overwhelming support, each receiving over 98.8% approval.

Notable changes include Dr. John H. Sampson's departure from the board, though he will continue as a clinical advisor. The election results demonstrated strong shareholder confidence, with key figures like Dr. Fahar Merchant and Ms. Karen Dawes receiving 99.25% and 99.35% of votes respectively.

Medicenna Therapeutics (OTCQX:MDNAF), a clinical-stage cancer immunotherapy company specializing in Superkines development, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

Dr. Fahar Merchant, President and CEO, will deliver a presentation on September 9th, 2025, at 2:30 PM EST at the Lotte New York Palace Hotel. The presentation will be available via webcast, with a 90-day replay period accessible through Medicenna's investor relations website.

Medicenna Therapeutics (OTCQX:MDNAF) reported its Q1 fiscal 2026 results, highlighting significant progress in its immunotherapy pipeline. The company ended Q1 with $20.5 million in cash, providing runway into mid-2026. Operating costs increased to $5.5 million, up from $4.0 million year-over-year, with net loss at $0.06 per share.

Key clinical achievements include promising MDNA11 results, with 30-50% response rates in high-dose patients and complete responses in pancreatic and melanoma cancers. The Phase 1/2 ABILITY-1 trial remains on track for top-line data in H2 2025. The company's IP portfolio expanded to 86 granted patents, strengthening its commercial potential.

R&D expenses increased to $4.2 million from $2.8 million, primarily due to ABILITY-1 Study expansion, while G&A expenses remained stable at $1.3 million.

Medicenna Therapeutics (OTCQX: MDNAF) has strengthened its intellectual property portfolio with five newly granted patents for its IL-2 and IL-4 Superkine platforms. The patents, which expire between 2033 and 2040, cover composition, formulation, combination, use, and therapeutic applications across major global markets.

Key patents include protection for MDNA11 in combination with anti-PD-1 antibodies and a novel formulation of bizaxofusp (MDNA55) for brain cancer treatment. The company's global IP portfolio now includes 86 granted or allowed patents, supporting their clinical pipeline in oncology and autoimmune diseases.

Medicenna Therapeutics (OTCQX: MDNAF) reported its fiscal year 2025 financial results and operational highlights, showcasing significant progress in its clinical programs. The company's lead drug MDNA11 demonstrated compelling anti-tumor activity with response rates of 30-50% in high-dose patients, including three cancer patients remaining tumor-free. Notably, a pancreatic cancer patient has maintained remission for 18 months without additional treatment.

The company reported a net loss of $11.8 million ($0.15 per share) for FY2025, compared to $25.5 million in FY2024. With $24.8 million in cash, Medicenna has runway into mid-2026. Operating costs increased to $20.4 million, primarily due to expanded clinical trial activities. The company plans to complete MDNA11 Phase 1/2 enrollment and report topline data from both monotherapy and combination arms with KEYTRUDA by year-end.

Medicenna Therapeutics has presented promising preclinical data for MDNA113, their novel tumor-targeted immunotherapy candidate, at the 2025 AACR Meeting. MDNA113 is a first-in-class anti-PD-1-IL-2 bifunctional Superkine designed to target IL-13Rα2, which is overexpressed in "immunologically cold" tumors.

The therapy shows potential in treating multiple cancer types, including pancreatic, liver, brain, breast, colon, and prostate cancer, affecting over 2 million patients worldwide. Key findings demonstrate:

• Preferential tumor localization lasting 72+ hours
• Enhanced tolerability through IL-13SK masking
• 100% protection in complete responders against tumor rechallenge
• Improved CD8+ T cell infiltration in tumor models

According to CEO Fahar Merchant, MDNA113's unique approach combines targeted delivery with conditional activation, potentially offering superior results compared to current anti-PD-1-IL-2 bispecifics in development.

Medicenna Therapeutics has presented updated clinical data from its ongoing Phase 1/2 ABILITY-1 study of MDNA11, a long-acting IL-2 super-agonist, at the 2025 AACR Annual Meeting. The study shows promising results both as monotherapy and in combination with KEYTRUDA:

• 10 patients achieved objective response (5 confirmed) in advanced/metastatic cancers resistant to immune checkpoint inhibitors
• 36% objective response rate (ORR) achieved in combination therapy
• 29.4% ORR achieved in monotherapy at ≥60 µg/kg dose
• Highest ORR of 50% observed in MSI-H patients and endometrial cancer patients

The treatment demonstrated an acceptable safety profile with over 90% of treatment-related adverse events being Grade 1-2 and transient. Two patients remain tumor-free and off-treatment after 2-3 years. Phase 2 combination dose expansion is now underway with MDNA11 at 90 µg/kg combined with KEYTRUDA.

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto. Dr. Fahar Merchant, President and CEO, will present on Monday, May 5, 2025, at 2:30 p.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will be accessible via webcast, with a 90-day replay available on Medicenna's Investor Relations website. This prestigious conference connects U.S., Canadian, and international investors with leading Canadian healthcare companies, facilitating corporate updates and one-on-one meetings.

Medicenna Therapeutics Corp. (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference in Las Vegas. Dr. Fahar Merchant, President and CEO, will present on April 9, 2025, at 2:00 p.m. Pacific Time at The Venetian Resort.

The presentation will be accessible via webcast through Medicenna's Investor Relations website, with replay available for 90 days. The two-day conference, scheduled for April 8-9, 2025, will feature one-on-one meetings, presentations, fireside chats, panels, and networking opportunities, bringing together select innovative companies and institutional investors.